Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 190-192

  Weiner, Louis M ^a   Alpaugh, R Katherine ^a   Von Mehren, Margaret ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Bispecific antibody; Cytotoxicity; HER2 neu CD16; Staphylococcal enterotoxin A

Indexed keywords

BISPECIFIC ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NACOLOMAB TAFENATOX; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG RESEARCH; FEVER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RIGOR; THROMBOCYTOPENIA;

ANTIBODIES, BISPECIFIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; RECEPTOR, ERBB-2; RECEPTORS, IGG; SUPERANTIGENS;

EID: 0030783183     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050430     Document Type: Article

References (10)

1. Alpaugh RK, Weiner LM (1997) Overview of clinical trials employing antibody-targeted superantigens. Adv Drug Rev (in press)
2. Clark JI, Alpaugh RK, Mehren M von, Schultz J, Gralow JR. Cheever MA, Ring DB, Weiner LM (1997) Induction of multiple anti-c-erhB2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother (in press)
3. Dohlsten M, Hansson J, Ohlsson L et al. (1995) Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 92:9791
4. Garcia de Palazzo IE, Gercel-Taylor C, Kitson J, Weiner LM (1990) Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and Fcγ receptor expressed by human large granular lymphocytes. Cancer Res 50:7123.
5. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Guedez Y, Kotb M, Vitek L, Persson R, Kelland T, Dohlsten M, Persson B, Weiner LM (1997) Superantigen-based immunotherapy: a phase I trial of LS4565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 15:1994
6. Weiner LM. Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK (1993) Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunology 151:1
7. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo IG (1993) A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94
8. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res 55:4586
9. Weiner LM, Clark JI, Ring DB, Alpaugh RK (1995) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and FcγRIII. J Hematother 4:453
10. Weiner LM, McAleer C, Schultz J, Persson B, Persson R, Dohlsten M, Vitek L, Giantonio BJ, Nielsen SE, Alpaugh RK (1997) Superantigen-targeted therapy: phase I escalating repeat dose trial of PNU-214565, A fusion protein composed of staphylococcal enterotoxin A (SEA) and C242 antibody Fab fragment in patients with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol 16:436a